Multiplex PCR is a highly sensitive molecular method for accurate detection of respiratory pathogens and provides a more rapid turnaround time (TAT) compared with other respiratory viral testing methodologies. Our microbiology laboratory switched from the Luminex xTAG respiratory viral panel (RVP) (http://www.luminexcorp.com), which detects 12 respiratory viruses with an assay time of 8.5 h, performed two to three times per week to the Biofire Diagnostics FilmArray respiratory panel (RP) (http:// filmarray.com), which detects 17 respiratory viral and three bacterial targets with an assay time of 1.2 h, performed 24 h a day/7 days per week. We compared the TAT between the two RVPs performed at different frequencies and determined the time to discontinuation of empiric oseltamivir among patients testing negative for influenza. All adult patients with an RVP test result reported between 1 December 2011 and 28 February 2012 performed on Luminex xTAG RVP (two to three times per week) and 1 December 2012 and 28 February 2013 performed on FilmArray RP (24 h a day/7 days per week) were evaluated for mean TAT.
The mean TAT for the Luminex xTAG RVP (two to three times per week) between 1 December 2011 and 28 February 2012 (n5230 assays) was 46.4 h compared with a mean TAT of 3.1 h (P,0.001) for FilmArray RP (24 h a day/7 days per week) between 1 December 2012 and 28 February 2013 (n5872 assays) (Fig. 1) . The mean time to discontinuation of empiric oseltamivir amongst patients with an RVP negative for influenza was 4 and 2 days for the Luminex xTAG RVP (n542) and FilmArray RP (n575) groups, respectively (P,0.001). The reduction in mean time to discontinuation of empiric oseltamivir resulted in cost savings of US$34.16 per patient (using a wholesale acquisition cost for oseltamivir of US$8.54 per dose), which during the 2012-2013 peak influenza season would be an overall cost saving of US$2527.84. The amount of oseltamivir utilized after we began using the FilmArray RP (24 h a day/7 days per week) would cost US$9564.80 (if all 112 influenza-positive patients received the standard 75 mg every 12 h dose for a duration of 5 days), in addition to US$2527.84 for those that would have received empiric therapy for a duration of 2 days prior to discontinuation following a negative influenza result, totalling US$12 009.64 in expenditure on oseltamivir during this time period. The cost savings in switching methodologies and increasing the frequency of assay performance were not evaluated; however, with 642 more assays run with the FilmArray RP in the subsequent influenza season and keeping in mind the additional cost associated with running the Luminex xTAG RVP (increased laboratory technician handling time and extra cost of the materials needed to perform the assay), the anticipated cost savings would be in favour of the FilmArray RP.
Consistent with previous literature, we found the use of the FilmArray RP to be associated with a significantly shorter mean TAT compared with the Luminex xTAG-RVP (3.1 versus 46.4 h) (Babady et 
